The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy

被引：0
|
作者：
Hongping Chen
Da Teng
Bowen Xu
Chunxiao Wang
Hua Wang
Wenjuan Jia
Lei Gong
Haibin Dong
Lin Zhong
Jun Yang
机构：
[1] Qingdao University,School of Medicine
[2] Yuhuangding Hospital,Department of Cardiology
[3] The Fourth School of Clinical Medicine of Qingdao University,undefined
[4] Binzhou Medical University,undefined
来源：
Journal of Cardiovascular Translational Research | 2023年 / 16卷
关键词：
SGLT2 inhibitor; Macrophage; Autophagy; Atherosclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：999 / 1009
页数：10
相关论文
共 50 条
  • [1] The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy
    Chen, Hongping
    Teng, Da
    Xu, Bowen
    Wang, Chunxiao
    Wang, Hua
    Jia, Wenjuan
    Gong, Lei
    Dong, Haibin
    Zhong, Lin
    Yang, Jun
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2023, 16 (05) : 999 - 1009
  • [2] Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin
    De Jonghe, Sandra
    Proctor, Jim
    Vinken, Petra
    Feyen, Bianca
    Wynant, Inneke
    Marien, Dirk
    Geys, Helena
    Mamidi, Rao N. V. S.
    Johnson, Mark D.
    CHEMICO-BIOLOGICAL INTERACTIONS, 2014, 224 : 1 - 12
  • [3] The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy
    Hualin Xu
    Jie Fu
    Qiang Tu
    Qingyun Shuai
    Yizhi Chen
    Fuyun Wu
    Zheng Cao
    Journal of Physiology and Biochemistry, 2024, 80 : 27 - 39
  • [4] The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy
    Xu, Hualin
    Fu, Jie
    Tu, Qiang
    Shuai, Qingyun
    Chen, Yizhi
    Wu, Fuyun
    Cao, Zheng
    JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY, 2024, 80 (01) : 27 - 39
  • [5] Invokana (Canagliflozin), an SGLT2 inhibitor, launched in the UK
    不详
    DIABETES OBESITY & METABOLISM, 2014, 16 (05): : 480 - 480
  • [6] Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin
    Esprit, Don H.
    Koratala, Abhilash
    NEPHROLOGY, 2018, 23 (05) : 493 - 493
  • [7] Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
    Kaushal, Shaveta
    Singh, Harmanjit
    Thangaraju, Pugazhenthan
    Singh, Jasbir
    NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, 2014, 6 (03) : 107 - 113
  • [8] Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes
    Nigro, Stefanie C.
    Riche, Daniel M.
    Pheng, Michelle
    Baker, William L.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (10) : 1301 - 1311
  • [9] The antidiabetic SGLT2 inhibitor canagliflozin reduces mitochondrial metabolism in a model of skeletal muscle insulin resistance
    VanDerStad, Lindsey R.
    Wyatt, Emily C.
    Vaughan, Roger A.
    DIABETIC MEDICINE, 2024, 41 (05)
  • [10] SGLT2 Inhibitors A Review of Canagliflozin
    Willson, Megan N.
    White, John R., Jr.
    US PHARMACIST, 2013, 38 (10) : HS13 - HS20
12345